Recruiting NCT06520488
A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: HRS-4642.
- Who it may be relevant to
- Registry conditions: Advanced Solid Tumors. Basic parameters: 18 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Phase IB/II Clinical Study of the Safety, Tolerability and Efficacy of HRS-4642 in Combination With Anti-tumor Agents in Subjects With Advanced Solid Tumors
Overview
To evaluate the safety and preliminary efficacy of HRS-4642 in combination with antineoplastic agents in subjects with advanced solid tumors with KRAS G12D mutations, and to determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D).
Interventions
- Drug HRS-4642
Treatment group Part I: HRS-4642 combined with SHR-A1921 Treatment group Part II: HRS-4642 combined with SHR-A1904 Treatment group Part II: HRS-4642 combined with AG
Primary outcome measures
- Stage 1: (IB Period):DLTs [Time frame: Within 28 days of the first dose]
- Stage 1: (IB Period): adverse events (AEs) [Time frame: Within 28 days of the first dos,About 1 year]
- Phase II: (Phase II):investigator-assessed ORR [Time frame: Assessed every 6 weeks,About 1 year]
Secondary outcome measures (7)
- Stage 1: (IB Period):Investigator-assessed objective response rate (ORR) [Time frame: Assessed every 6 weeks,About 1 year]
- Phase II: (Phase II):DCR [Time frame: Assessed every 6 weeks,About 1 year]
- Phase II: (Phase II):DoR [Time frame: Assessed every 6 weeks,About 1 year]
- Phase II: (Phase II):OS [Time frame: Assessed every 6 weeks+ About 1 year]
- Phase II: (Phase II):PFS [Time frame: Assessed every 6 weeks,About 1 year]
- Phase II: (Phase II):OS [Time frame: Assessed approximately once every 1 month,About 1 year]
- Phase II: (Phase II):Incidence and severity of AEs [Time frame: Assessed approximately once every 1 month,About 1 year]
Eligibility criteria
Inclusion criteria
- Able and willing to provide a written informed consent
- Age 18-75 years old (inclusive) at the time of signing the informed consent form
- Male or female
- ECOG score of 0 or 1
- Expected survival ≥ 12 weeks
- At least one measurable lesion according to RECIST v1.1 criteria
Exclusion criteria
- Any other condition that, in the judgment of the investigator, may increase the risk of participating in the study, interfere with the results of the study, or be unsuitable for participation in this study
- Presence of uncontrollable psychiatric illness and other conditions such as known alcoholism, drug or substance abuse, criminal detention, etc., that affect the completion of the study procedures
- Known hypersensitivity to any component of HRS-4642; History of severe allergic reactions to other monoclonal antibodies/fusion protein drugs; Known history of severe hypersensitivity to antineoplastic agents in combination
- Received other major surgery other than diagnosis or biopsy within 28 days before the first dose; Minor traumatic surgery (biopsy, laparoscopy, and drainage) within 7 days prior to the first dose; Presence of non-healing wounds (severe, non-healing, or dehiscence), untreated fractures
- Subjects who are participating in other clinical studies or whose first dose is less than 4 weeks from the end of the previous clinical study (last dose), or who have 5 half-lives of this investigational drug, whichever is shorter
- Use of a live attenuated vaccine within 28 days prior to the first dose of study medication, or anticipated need for a live attenuated vaccine during study treatment
- Have a history of immunodeficiency, including a positive HIV test, other acquired or congenital immunodeficiency diseases, or a history of organ transplantation
- Those who have active pulmonary tuberculosis infection within 1 year before enrollment, or those who have a history of active pulmonary tuberculosis infection more than 1 year ago but have not been formally treated
- Active hepatitis B
- Presence of clinically significant acute or chronic pancreatitis
- Poorly controlled or severe cardiovascular and cerebrovascular diseases, arterior/venous thrombotic events within 6 months prior to study entry
- Presence of gastrointestinal obstruction or presence of symptoms and signs of gastrointestinal obstruction within 6 months prior to the start of study treatment, but screening can be performed if surgical treatment has been performed and the obstruction has been completely resolved
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
China · 1 center
- Renji Hospital, Shanghai Jiao Tong University School of Medicine — Shanghai
Publications
- Cui J, Jiang K, Li W, Ni S, Zong H, Du J, He Y, Liu Z, Kong G, Zhang Y, Li X, Han H, Yao F, Chen Y, Zhou M, Wang L. KRAS-G12D inhibitor HRS-4642 plus chemotherapy in advanced KRASG12D-mutant pancreatic cancer: a phase 1b/2 trial. Nat Med. 2026 Jul 9. doi: 10.1038/s41591-026-04538-9. Online ahead of print. PMID 42426224
Identifiers
NCT: NCT06520488 · HRS-4642-202